Charles River - JP Morgan Conference Presentation
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP REVENUE GROWTH
TO NON-GAAP REVENUE GROWTH, ORGANIC (UNAUDITED)
Twelve Months Ended September 24, 2022
Revenue growth, reported
Increase due to foreign exchange
Contribution from acquisitions (2)
Impact of divestitures (3)
Non-GAAP revenue growth, organic
(4)
(1)
Total CRL
RMS Segment
DSA Segment
MS Segment
10.4 %
4.0%
10.7 %
15.7 %
2.6%
2.1 %
(3.6)%
(4.1)%
2.4%
(0.5)%
3.7 %
(12.2)%
1.8%
7.5%
- %
1.4 %
11.2 %
9.5%
12.6 %
8.6 %
(1) Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a
meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items
which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance.
The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations
prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results
consistent with applicable rules, regulations and guidance.
(2)
The contribution from acquisitions reflects only completed acquisitions.
(3) The Company sold both its RMS Japan operations and its gene therapy CDMO site in Sweden on October 12, 2021. This adjustment represents
(4)
the revenue from these businesses for all applicable periods in 2021.
Organic revenue growth is defined as reported revenue growth adjusted for acquisitions and foreign exchange.
Charles River - JP Morgan Conference Presentation
26View entire presentation